NCT01019252.

Methods	Design: RCT Number of arms: two
Participants	Country: USA Sample size calculation: not reported Target sample size: 66 Eligible age: age 14 to 18 years Eligible sex: all Inclusion criteria: age 14 to 18 years in high school principal diagnosis of ADHD stable prescription of medications for ADHD childhood onset of ADHD clinically significant ADHD symptoms Exclusion criteria: comorbidity of: organic mental disorders; active substance abuse or dependence; diagnosis of conduct disorder; mental retardation or pervasive developmental disorder active suicidality other condition interfering with consent or participation previous history of CBT therapy in adolescence
Interventions	Group one: behavioural: compensatory executive skills training, cognitive behavioural therapy. Participants provided with education about ADHD and instruction in organisational skills, reducing distractibility, and adaptive thinking. Twelve weekly treatment sessions Group two: no intervention. Cross‐over design with the participants on the waiting list receiving CBTafter the four‐month assessment
Outcomes	ADHD symptoms: ADHD‐RS, child‐ and parent‐rated; CGI scale, clinician‐rated Secondary symptoms of ADHD (e.g. mood) Time of assessment: before randomisation, and at follow‐up, four months and eight months after randomisation
Notes	Study ID:NCT01019252 Sponsorship source: R34MH083063, US NIH Grant/Contract; DDTR B4‐TBI, National Institute of Mental Health Study start date: October 2009 Study end date: August 2012 Status: completed Declared conflict of interest: not reported Comments: none Registrant's name: Steven A Safren Institution: Massachusetts General Hospital Address: not reported Email: not reported Telephone: not reported

^{ADHD: attention deficit hyperactivity disorder
 ADHD‐ RS: Attention Deficit Hyperactivity Disorder ‐ Rating Scal
 CBT: cognitive behavioural therapy
 CGI: Clincal Global Impressions 
 RCT: randomised controlled trial}